Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.37M$4.37Mderived+40.0% vs Q4 2016 Net Income$20.01M$20.01MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,731,000+102.6% Operating Incomederived-$3,298,000N/M Operating Cash Flowderived-$2,379,000N/M Free Cash Flowderived-$2,379,000— Margins · derivedGross margin62.5%+19.3 pt vs Q4 2016
Operating margin-75.5%
Net margin458.0%+645.7 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 23, 2018 · 82 d after period end